key: cord-0786810-dfj7yxef
authors: Martin, C. J.; McDonald, S.; Luteijn, M.; Robertson, J.; Letton, W.
title: A model framework for projecting the prevalence and impact of Long-COVID in the UK
date: 2021-05-20
journal: nan
DOI: 10.1101/2021.05.18.21252341
sha: cab55eeb9ff3466279ea348ab8ad71cf1cf16cb9
doc_id: 786810
cord_uid: dfj7yxef

Background The objective of this paper is to model lost Quality Adjusted Life Years (QALYs) from symptoms arising from COVID-19 in the UK population, including symptoms of 'long-COVID'. The scope includes QALYs lost to symptoms, but not deaths, due to acute COVID-19 and long COVID. Methods The prevalence of symptomatic COVID-19, encompassing acute symptoms and long-COVID symptoms, was modelled using a decay function. Permanent injury as a result of COVID-19 infection, was modelled as a fixed prevalence. Both parts are combined to calculate QALY loss due to COVID-19 symptoms. Results Assuming a 60% final attack rate for SARS-CoV-2 infection in the population, we modelled 299,719 QALYs lost within 1 year of infection (90% due to symptomatic COVID-19 and 10% permanent injury) and 557,754 QALYs lost within 10 years of infection (49% due to symptomatic COVID-19 and 51% due to permanent injury). The UK Government willingness-to-pay to avoid these QALY losses would be {pound}17.9 billion and {pound}32.2 billion, respectively. Additionally, 90,143 people were subject to permanent injury from COVID-19 (0.14% of the population). Conclusion Given the ongoing development in information in this area, we present a model framework for calculating the health economic impacts of symptoms following SARS-CoV-2 infection. This model framework can aid in quantifying the adverse health impact of COVID-19, long COVID and permanent injury following COVID-19 in society and assist the proactive management of risk posed to health. Further research is needed using standardised measures of patient reported outcomes relevant to long COVID and applied at a population level.

The objective of this paper is to model lost Quality Adjusted Life Years (QALYs) from symptoms arising 22

from COVID-19 in the UK population, including symptoms of 'long-COVID'. The scope includes QALYs 23 lost to symptoms, but not deaths, due to acute COVID-19 and long COVID. 24

The prevalence of symptomatic COVID-19, encompassing acute symptoms and long-COVID symptoms, 26

was modelled using a decay function. Permanent injury as a result of COVID-19 infection, was 27 modelled as a fixed prevalence. Both parts are combined to calculate QALY loss due to symptoms. 29

Assuming a 60% final attack rate for SARS-CoV-2 infection in the population, we modelled 299,719 31

QALYs lost within 1 year of infection (90% due to symptomatic COVID-19 and 10% permanent injury) 32

and 557,754 QALYs lost within 10 years of infection (49% due to symptomatic COVID-19 and 51% due 33

to permanent injury). The UK Government willingness-to-pay to avoid these QALY losses would be 34 £17.9 billion and £32.2 billion, respectively. Additionally, 90,143 people were subject to permanent 35 injury from COVID-19 (0.14% of the population). 36

Given the ongoing development in information in this area, we present a model framework for 38 calculating the health economic impacts of symptoms following SARS-CoV-2 infection. This model 39 framework can aid in quantifying the adverse health impact of COVID-19, long COVID and permanent 40 injury following COVID-19 in society and assist the proactive management of risk posed to health. 41

Further research is needed using standardised measures of patient reported outcomes relevant to 42 long COVID and applied at a population level. 43

In December 2019, a series of pneumonia cases, now known to be caused by the novel SARS-Cov-2 45 virus, emerged in Wuhan, China (1). The novel SARS-Cov-2 virus quickly spread across the globe and 46

on March 11 th , 2020, the WHO made the assessment that COVID-19 can be characterised as a 47

pandemic. As of April 2021, the global confirmed death toll stands at over 1.4 million, with over 48 150,000 deaths mentioning COVID-19 on the death certificate in the UK (2,3). 49

Over the course of the COVID-19 pandemic, it has emerged that some COVID-19 patients suffer 50 symptoms long after initial infection.The National Institute for Health and Care Excellence (NICE) has 51 defined three phases to symptoms following . First, 'Acute COVID-19 infection' covers 52 the period of active infection up to 4-weeks post-infection. Second, 'Ongoing symptomatic covers the period when infection should have ceased but persisting effects from the infection that 54

may take time to heal may be present from 4 and 12-weeks post-infection. Third, 'Post-COVID-19 55 syndrome' is defined as 'Signs and symptoms that develop during or following an infection consistent 56

with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis.' 57

Long COVID describes both ongoing symptomatic COVID-19 as well as post-COVID-19 syndrome. 58

Documented symptoms for long COVID include breathlessness, fatigue, myalgia, chest pains and 59

insomnia (5). 60

Post-COVID-19 syndrome may persist long after active infection has ceased and in some cases 61 symptoms will be permanent. Lung scarring following coronavirus related ARDS or from the high-62 pressure mechanical ventilation used in its treatment has been widely documented (6). In a study of 63 patients with acute respiratory distress syndrome about a third of those who were previously 64 employed were still unemployed 5-years later (7) varying duration and differing aetiologies, but that all are self-limiting and will eventually recover. The 87

COVID injured group includes people in the post-COVID-19 syndrome group that may have persisting 88 A model framework for projecting the prevalence and impact of Long-COVID in the UKA model framework for projecting the prevalence and impact of Long-COVID in the UK 18/05/2021 4 symptoms as a result of permanent injury following infection and associated treatment. These 89 symptoms are assumed to be permanent for the purpose of modelling. 90

We modelled QALYs lost due to COVID-19 illness, but not deaths, in the UK population of 66.6 million. 93

Our baseline model assumed a 60% attack rate at day 0 and no reinfections. Univariate sensitivity 94 analysis was carried out on key model parameters. Symptom prevalence for the SARS-Cov-2 infected 95 is modelled using a decay function based on the national Coronavirus Infection Survey (9). A second 96 group, the COVID permanently injured, is kept at a fixed prevalence. Both symptomatic COVID-19 97 cases and the permanently injured were divided into three mutually exclusive treatment groups: non-98 hospitalised, ward-based care and ITU care (Figure 1) . For the symptomatic COVID-19 cases, COVID-99

19-related QALY loss differed by treatment group, while the probabilities of emerging with permanent 100 injury also vary by treatment group. 101

The core of the model is a calculation of the cumulative days lived with symptoms and/or permanent 102 injury up to the modelled time-horizon, multiplied by the number of Quality Adjusted Life Years lost 103

per day for those with symptoms and discounted over time. showing higher and an app-based survey (16) showing a lower prevalence of symptoms than the 118 national Coronavirus Infection Survey (9) (Figure 2) . The national Coronavirus Infection Survey is 119 considered most relevant as it contains the largest sample and provides a reference to the UK general 120 population prevalence. The Coronavirus Infection Survey consists of a random, a-priori, selected 121 sample that is invited for COVID tests and therefore would cover asymptomatic and symptomatic 

Home . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 20, 2021. ; https://doi.org/10.1101/2021.05.18.21252341 doi: medRxiv preprint A model framework for projecting the prevalence and impact of Long-COVID in the UKA model framework for projecting the prevalence and impact of Long-COVID in the UK 18/05/2021 5 cases. Two key data points provide the prevalence of symptoms at 5 and 12-weeks, which were 123 approximately 20% and 10% respectively. A natural history of symptom prevalence over time was 124 fitted to all infections in the model by fitting an exponential decay curve on these two data points, 125 plus a 50% symptom prevalence assumed at t = 0 (Equation 1). 126

Equation 1 127 , = 0.4548 * −0.132 *

Where: 129

• is the prevalence of any symptoms at time t in weeks following infection. 130

• Decay function constant = 0.4548 and rate of decay = -0.132 derived using CIS study data 131 points. 132 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 20, 2021. ; https://doi.org/10.1101/2021.05.18.21252341 doi: medRxiv preprint A model framework for projecting the prevalence and impact of Long-COVID in the UKA model framework for projecting the prevalence and impact of Long-COVID in the UK 18/05/2021 6 set at 72% for ITU and 60% for ward patients (15), while for non-hospitalised patients it is set at 16% 152 (interpolated from the COVID Infection survey (9)). 153

About a third of previously employed patients with ARDS were still unemployed 5-years later (7). We 154 assume that disability arising from the illness was the sole cause of unemployment and that a fraction 155 who are injured may manage to return to work, implying an injured figure higher than 33%. Reflecting 156 this uplift, we estimate that 50% of the ITU survivors with symptoms at 6 weeks post-COVID will be 157 left permanently injured. For the ward-based group and the non-hospitalised group, we assume 5% 158 permanently injured and 0.5% permanently injured amongst survivors symptomatic at 6 weeks post-159 COVID, respectively (10% and 1% of the ITU rate, respectively). Using the breakdown between non-160

hospitalised ( non-hospitalised population. We assumed the utility loss for non-hospitalised COVID-19 patients with 174 persistent symptoms to be the same as for the ward-based patients at -10%. 175

The utility for the permanently injured group is taken from a secondary health-economic analysis of a 176 randomised controlled trial of 795 patients ventilated in critical care in the UK (21). At one-year post-177 discharge, mean utility was 0.58, both for those above and below the age of 65. Taking into account 178 the reference population utility for the UK (0.856) (22), the ARDS specific utility at 1-year is calculated 179 at 0.58/0.856 = 0.68. 180

Aggregate COVID-specific utility for the symptomatic COVID cohort was calculated at -11%, using a 181 weighted sum of the utilities for the three treatment groups (ward, ITU and population). 182 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 20, 2021. ; https://doi.org/10.1101/2021.05.18.21252341 doi: medRxiv preprint 

Prevalence function for prevalence of symptoms post COVID-19 by the day.

= . − . C = 0.4548 l = 0.132

Fitted to the results of the CIS long-COVID report December 2020 (9) plus an assumed 50% symptoms at t = 0.

key assumption update as evidence emerges

Constant term 0.3638-0.5458

Prevalence of symptoms at 6-weeks for survivors of ITU.

Prevalence of symptoms at 6-weeks in ward-care only survivors.

Proportion of ITU survivors with persistent symptoms at 6-weeks who are permanently injured.

An assumption based on the observation that 33% of those employed at the time of admission to ITU with ARDS are still unemployed 5-years later (7) with an up-lift applied to reflect those returning to work while permanently injured.

Placeholder estimate to be updated when evidence emerges

Proportion of ward-care survivors with persistent symptoms at 6-weeks who are permanently injured.

An assumption that the prevalence is 10% of the ITU prevalence.

Proportion of nonhospitalised cases with persistent symptoms at 6-weeks who are permanently injured.

An assumption that the prevalence is 10% of the ward-care prevalence.

Proportion of all known cases surviving critical care.

Calculated from the proportion of cases admitted to ITU and the survival rate on ITU.

Survival and hospitalisation rates may change as treatment improves, vaccine reduce disease risk, virus variants impact fatality.

Proportion of all known cases surviving ward.

Calculated from the proportion of cases admitted to a hospital ward and the survival rate on the ward. Proportion of all known cases that are nonhospitalised that survive.

The proportion of cases not admitted on the assumption that the mortality rate is negligible in this group. Adjusted prevalence of permanent injury for all infections, known and unknown.

Calculated from the prevalence of permanent injury in known cases and the proportion of all infections that are identified as cases. Key assumption update as evidence emerges.

Annual discount rate for future QALYs

£60,000

184 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 20, 2021. ; https://doi.org/10.1101/2021.05.18.21252341 doi: medRxiv preprint A model framework for projecting the prevalence and impact of Long-COVID in the UKA model framework for projecting the prevalence and impact of Long-COVID in the UK 18/05/2021 8

We modelled QALY loss due to COVID-19 symptoms, but not deaths. year, reducing the time horizon from 10 to 1-year reduced discounted QALY loss by only 44.3%. A 207 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 20, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 reduction or increase in attack rate directly translates into a similar reduction or increase in QALY loss, 208 while the model is less sensitive to parameters to do with QALY loss and prevalence for symptomatic 209 COVID-19 and permanent injury as QALY loss is split between these two conditions. On shorter 210 timeframes, the model would be more sensitive to assumptions around symptomatic COVID-19 211 prevalence and QOL loss as symptomatic COVID-19 is a larger proportion of total QALY loss at shorter 212 timeframes. 213 Figure 4 : Results of sensitivity analysis on key parameters 214 215 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 20, 2021. ;

We modelled QALY loss due to COVID-19 symptoms and permanent injury in the UK population. To 217 the best of our knowledge, this is the first such study on a UK population using UK data. Basu and 218 Gandhay modelled the QALY impact of averting a single COVID-19 infection in an American setting (24) 219 and reported QALY loss due to symptomatic (outpatient) COVID-19 of 0.007 (95% CI: 0.002-0.011) per 220 COVID-19 infection. This compares to our 0.0075 and 0.0135 for 1-and 10-year horizons, respectively. 221

A further 0.002 QALY loss to family members due to symptomatic COVID-19 and 0.048 QALY due to 222 COVID-19 deaths was modelled by Basu and Gandhay, both of which was out of our scope. Basu and 223 Gandhay assumed utility loss for symptomatic outpatients of 0.43 (based on utility of H1N1 patients 224 on the day of index medical visit), compared to our 0.10, based on COVID-19 symptomatic patients on 225

average 48 days post-discharge. Given the longer timeframe of our model (including modelled  226 symptomatic infections), we felt 0.10 is appropriate. In Basu and Gandhay's model, 0.005% of 227 symptomatic patients recover with permanent kidney injury, while in our model, 0.2% of all infections 228 resulted in permanent injury. 229

Various studies have reported widely varying estimates of symptom prevalence (Figure 2 ). At 12 230

weeks, the Coronavirus Infection Survey (shown as Population) reports a prevalence of any symptoms 231 of 9.9% but the Arnold study reports a prevalence of 74% (shown as Hospitalised). The Arnold study 232 sample includes hospitalised patients only whereas the CIS study is population-based. Even when 233

considering hospitalisation as a risk factor and the different study populations, the prevalence 234 variation appears larger than expected. The Sudre study (shown as App-users) conducted from a 235 COVID app reported a lower symptom prevalence of 2.3%. This might reflect sampling and recording 236 biases as the users were self-selected and responsible for the recording symptoms. The means of 237 eliciting responses in symptom studies can have a significant impact on the estimated prevalence thus 238

making comparison between studies difficult (25-27). Symptom prevalence studies are also 239 complicated by adjusting for background prevalence as well as varying definitions of symptoms. 240

QALYs can be used to estimate disease burden as it is a measure that reflects both the quantity and 241 quality of life. By integrating the impact of disease on mortality and morbidity into a single index, 242

comparisons between different diseases can be made. For current modelling purposes, it was the most 243 appropriate measure to estimate the prevalence and health impact long-COVID due to its 244 standardised, reproducible and summarised characteristics of HRQoL. However, the effects of COVID-245 19 are not limited to health. There are economic impacts to individuals and the country as well as 246 wellbeing impacts on family members of those symptomatic. Additionally, measures taken to limit the 247 spread of SARS-Cov-2 impact wellbeing and the overall economy (28). 248

Health and Care Services

Proactive care and tailored intervention support will be required in order to locate and accommodate 251 the needs of these patients in the most appropriate setting. We second the recommendation from 252

Halpin et al. that rehabilitation services should be planned "to manage these symptoms appropriately 253

and maximise the functional return of COVID-19 survivors" (15) There will be a lasting health burden 254 within our society for those who are COVID injured who will require ongoing support. Without 255 adequate planning this may put further pressures on NHS resources. 256

Prevention is better than cure. We provide these numbers as health economic rationale or a 257 willingness to pay to avoid an accumulation of injury due to COVID-19. This provides further 258 justification for the vaccination programme, which has been shown to provide significant reduction in 259 severe disease outcomes (29, 30) . Given the socio-economic disparity in the pandemic burden, this 260 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 20, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 may provide justification for spending which seeks to reduce health inequalities such as tailored public 261 health messaging, vaccination delivery, and community access to care. In addition, this provides 262 support for non-pharmaceutical interventions that reduce the transmission of the SARS- Societal and economic 264 For the Symptomatic COVID-19 cohort, return to work may be delayed causing increased claims on 265 statutory sick pay, group employer or individual income protection insurance. For the COVID-injured 266 cohort, some may not return to fully to work. This may cause increased claims on government 267 unemployment and disability benefits. Both cohorts would benefit from flexibility in working 268

arrangements and return to work to better accommodate the individuals' needs and ensure continued 269 employability. 270

Given the socio-economic disparity in the pandemic burden, there may be a disparity in the economic 271 impact of permanent injury from COVID-19 which warrants further investigation to prevent a 272 generational widening of the health inequality gap. Some in society have been, and are, at increased 273 risk of infection due to their occupation. We agree with the calls for "further research into the role of 274 repeated exposure to SARS-Cov-2 in a healthcare delivery setting and or in the community, and role 275 of the repeated exposures leading to autoimmune mediated responses"(31). 276

Limitations 277 The mechanisms of underlying pathogenesis and resulting symptoms of COVID-19 is not yet fully 278

understood. Although NICE have published a working definition, this may be subject to change. This 279 model estimates a disease that is evolving and as such, its ability to predict long-term outcomes will 280 be limited. There is uncertainly around some of the parameters being used in the model and a number 281 of assumptions had to be made. Survival rates of ward and ITU care were based on 2020 data and 282 could since have improved as improvements are being made in care for COVID-19 patients. Improved 283 knowledge on treatment for COVID-19 in wards and ITUs could also reduce the proportion of 284 permanently injured amongst survivors. 285

The quality of the symptom prevalence data used could be improved by standardising measurement 286 and recording of symptoms. Currently data is being gathered using different types of questionnaire in 287 different mediums e.g., Halpin (2020) developed their own COVID-19 rehabilitation telephone 288 screening tool, Arnold (2020) used the SF-36 questionnaire and Sudre (2020) used a self-reporting 289 questionnaire via an app. Standardised and validated questionnaires and tools exist and are used to 290 record patient reported outcomes (PROs). These include the St George's respiratory questionnaire 291 and the MRC dyspnoea scale (32,33). However, these are often disease-specific and may not be 292 appropriate for use in long-COVID patients. In addition, HRQoL questionnaires like SF-36 maybe too 293 general and may not capture all effects resulting from the multiple possible symptoms of COVID-19. 294

The Coronavirus Infection Survey study was used to inform the prevalence of ongoing symptoms from 295 diagnosis. It was the study with the largest sample and it also reflected the general population 296 prevalence due to the sampling methods used. Currently, we know the prevalence of ongoing 297 symptoms up to 12-weeks while the pandemic has lasted for more than 1-year so this is a relatively 298 short timeframe evidence base. As the survey continues to collect more data, the prevalence figures 299 could be updated to better reflect long-term outcomes. 300

Our calculation of infections that result in long-COVID uses fatigue as the most common symptom 301 post-discharge (15). This symptom was used as it was the most commonly reported in the symptom 302 prevalence studies. However, fatigue is also a commonly reported symptom in the general population 303 and prevalence varies. One review of fatigue as a symptom in 1992 found prevalence estimates in the 304 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 20, 2021. ;  general population ranging from 4% to 45% (26). Therefore, when a patient reports 'fatigue' it is not 305 known if the symptom is due to long-COVID or other factors. In addition, the interviewer asks the 306 interviewee to reference the time of interview and to a pre-COVID state which may result in recall 307

bias. 308

One of the assumptions of the model is that the average lost QALY rate for symptomatic patients in 309

shorter durations is similar to the Long-COVID lost QALY rate. This will affect how well the lost QALY 310 rate estimated by the model reflects the actual HRQoL of long-COVID. Again, as more data is collected 311

on HRQoL in patients with persistent symptoms, these limitations can be reconciled. 312

This article describes a model for estimating the health impact of COVID-19 symptoms, including long-314 COVID and permanent injury from COVID-19. Quality adjusted life-years lost are used to present a 315 standardised measure of the impacts and uses the HM Treasury to quantify the impact in monetary 316 terms. The model framework is presented such that it can be updated with information as more 317 reliable data accumulates. Based on the current parameterisation, 557,754 QALYs would be lost over 318

10-years, 286,454 to permanent injury as a result of COVID-19 and 271,300 from symptoms of COVID-319 19 across all timescales. An estimated 90,142 people could be left living with significant impairments 320 as a result of injury from This model framework highlights just some of the factors that will influence the impact of the Long-322 COVID burden in our society, our limited understanding of the condition to date, and the limited 323 information available. There is great uncertainty in the prevalence of symptoms over time as a result 324 of lack of standardisation in methods used to measure it. 

Clinical features of patients infected with 342 2019 novel coronavirus in Wuhan

World Health Organization. Coronavirus disease (COVID-19) pandemic

Patient outcomes 351 after hospitalisation with COVID-19 and implications for follow-up: results from a prospective 352 UK cohort

Long term respiratory complications of covid-19

Return to 357 work after critical illness: a systematic review and meta-analysis

Clinical course and risk factors for mortality of 361 adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Recovery and 369 outcomes after the acute respiratory distress syndrome (ARDS) in patients and their family 370 caregivers

Disability 5 Years after Acute Respiratory Distress Syndrome

Long-term clinical 377 outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory 378 syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review 379 and meta-analysis

Construction of a demand and capacity 382 model for intensive care and hospital ward beds, and mortality from COVID-19

Estimating 386 (quality-adjusted) life-year losses associated with deaths: With application to COVID-19

Postdischarge symptoms 390 and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation

Attributes and 394 predictors of Long-COVID: analysis of COVID cases and their symptoms 2

Covid Symptoms Study App. MedRxiv [Internet

Features of 20 398 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation 399 Protocol: Prospective observational cohort study

ICNARC. ICNARC report on COVID-19 in critical care: England, Wales and Northern Ireland

COVID-19 Daily Deaths [Internet]. england.nhs.uk

COVID-19) Infection Survey: antibody data for the UK

One-year resource utilisation, 411 costs and quality of life in patients with acute respiratory distress syndrome (ARDS): 412 Secondary analysis of a randomised controlled trial. J Intensive Care

Population norms for 415 the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries

Quality-Adjusted Life-Year Losses Averted With Every COVID-19 Infection 421 Prevented in the United States. Value Heal

Prevalence of post-traumatic stress disorder, 424 acute stress disorder and depression following violence related injury treated at the 425 emergency department: a systematic review

Assessment, 429 and Treatment of Mild Traumatic Brain Injury and Posttraumatic Stress Disorder. J Head 430 Trauma Rehabil

The epidemiology of fatigue: more questions than answers

Costing the COVID-19 Pandemic: An 436

Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom

Value Heal

Safety 440 and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in 441 young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Efficacy and Safety of the 445 mRNA-1273 SARS-CoV-2 Vaccine

From doctors as patients: 448 a manifesto for tackling persisting symptoms of covid-19

Prevalence and diagnosis of chronic respiratory 451 symptoms in adults

Evaluation of Clinical Methods for Rating Dyspnea

A model framework for projecting the prevalence and impact of Long-COVID in the UKA model framework for projecting the prevalence and impact of Long-COVID in the UK A model framework for projecting the prevalence and impact of Long-COVID in the UKA model framework for projecting the prevalence and impact of Long-COVID in the UK